nderstanding the usefulness of the PEAR-BIO platform in patients with kidney cancer
Not Applicable
- Conditions
- Patients undergoing surgery for renal cell carcinomaCancer
- Registration Number
- ISRCTN10001405
- Lead Sponsor
- Ourotech Limited (trading as Pear Bio)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
1. Aged 18 years old and over
2. Patients with operable kidney cancer
3. Able to give informed consent
4. Able to give 40 ml of blood and surgical sample yields >= 0.4 g of cancerous tissue
Exclusion Criteria
1. Inoperable or metastatic kidney cancer
2. Pre-operative haemoglobin levels below 120g/l
3. Patients who have already commenced chemotherapy, targeted therapy, immunotherapy or radiotherapy
4. Recurrence of cancer from any other site than the kidney
5. Any other disease or finding that renders the patient at high risk of treatment complications or interferes with obtaining informed consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method